Gadeta's Series A Round

Gadeta raised a round of funding on March 29, 2016.

Gadeta has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (γδ) T-cell receptors (TCRs) with an enhanced anti-cancer reactivity.…

Articles about Gadeta's Series A Round: